Skip to main content

Resverlogix Corp(RVX-T)
TSX

Today's Change
Real-Time Last Update

Stocks in play: Resverlogix Corp.

Baystreet - Wed Oct 4, 2023

Today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells" in the journal Biomedicines. Resverlogix Corp. shares T.RVX are trading unchanged at $0.07.

Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

opinion
Four reasons why wealthy investors should hold farmland in their portfolios
Andrea Gruza